Cellectar Biosciences Inc (OQ:CLRB)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 100 Campus Drive
FLORHAM PARK NJ 07932
Tel: 1-212-9153820
Website: https://www.cellectar.com
IR: See website
<
Key People
James V. Caruso
President, Chief Executive Officer, Director
Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Jarrod Longcor
Chief Operating Officer
Andrei Shustov
Senior Vice President - Medical
Shane Lea
Chief Commercial Officer
 
Business Overview
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom's macroglobulinemia (WM).
Financial Overview
For the fiscal year ended 31 December 2023, Cellectar Biosciences Inc revenues was not reported. Net loss increased 33% to $38M. Higher net loss reflects Reaserch and development increase of 45% to $27.7M (expense), General and administrative increase of 48% to $1.9M (expense), General and administrative increase of 6% to $8.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.05 to -$3.11.
Employees: 20 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $99.41M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$38.77M as of Dec 31, 2023
Net annual income (TTM): -$37.98M as of Dec 31, 2023
Free cash flow (TTM): -$33.24M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 32,260,510 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.